|
Mr. Koester has over 15 years of experience in the clinical development and FDA approval of ophthalmic drugs in AMD, allergy, glaucoma, inflammation and pain. With a background and training in biostatistics, Mr. Koester helped grow Novartis Ophthalmics from a small start-up division within Ciba Vision, to a large international ophthalmic pharmaceutical company within Novartis. | 